|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute of Allergy and Infectious Diseases (NIAID) <https://www.niaid.nih.gov/> For Immediate Release: Monday, August 29, 2022 CONTACT: Elizabeth Deatrick, (301) 402-1663, <email:niaidnews@xxxxxxxxxxxxx> MEDIA ADVISORY SARS-COV-2 ANTIGEN LEVELS LINKED TO PATIENT OUTCOMES WHAT: The amount of SARS-CoV-2 antigen measured in the blood of patients hospitalized with COVID-19 is associated with illness severity and other clinical outcomes, according to a new study published in the Annals of Internal Medicine. Following
the ACTIV-3 trial < https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials#activ3> of COVID-19 therapeutics in people hospitalized with COVID-19, researchers from the National Institute
of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators analyzed levels of SARS-COV-2 antigen in blood samples taken from study participants and assessed the association of those levels with disease progression.
Higher levels of viral antigen in the blood, which could indicate ongoing SARS-CoV-2 replication, correlated with more severe disease. The authors suggest that SARS-CoV-2 antigen levels hold promise as a biomarker, or a measurable substance, to predict which
patients hospitalized with COVID-19 have a higher risk of worse outcomes. The ACTIV-3 trial enrolled people hospitalized with COVID-19 between August 2020 and November 2021. Participants contributed a baseline blood sample and were then randomized to receive either an experimental COVID-19 therapeutic or a placebo.
All participants received the antiviral remdesivir unless contraindicated. In this follow-up analysis, the researchers examined 2,540 participant baseline blood samples for SARS-CoV-2 antigen levels.
The researchers assessed the relationship between each participant’s SARS-CoV-2 blood antigen levels and their time to discharge from the hospital, as well as their pulmonary symptoms at day five of the trial—whether they had stayed the
same, worsened, or improved since enrollment. With all this information in hand, the researchers conducted statistical analyses to determine if plasma antigen levels were associated with the participants’ pulmonary function when they gave the blood sample—and
whether they could predict how the participants would fare over time. In addition, the researchers examined the relationship between a number of participant and viral characteristics and antigen levels. The analysis revealed a strong correlation between higher SARS-CoV-2 antigen levels (≥1000 nanograms per liter) and worse pulmonary function at the time of enrollment. Importantly, participants with higher SARS-CoV-2 antigen levels in the
blood at enrollment generally had decreased pulmonary function at day five, regardless of the severity of their illness at the time of study entry, and took longer to be released from the hospital. High blood antigen levels also correlated with some known
risk factors for worse illness, such as being male. Three additional participant characteristics were found to correlate with lower antigen levels: the presence of SARS-CoV-2 antibodies, exposure to remdesivir prior to enrollment and longer time in hospital
prior to enrollment. Finally, participants infected with the delta variant had higher antigen levels than those infected with prior circulating strains. The researchers concluded that antigen levels in the blood are likely a marker of ongoing viral replication
and could be useful for predicting a patient’s disease progression and likely outcomes once they are admitted to the hospital. The authors note that these results suggest that a precision medicine approach could be helpful in future clinical trials of antiviral
therapy. For instance, antigen levels could help determine those patients most likely to benefit from therapies directed at fighting the virus. ARTICLE: Rogers et al. The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19. Annals of Internal Medicine DOI: 10.7326/M22-0924 (2022). WHO: H. Clifford Lane, M.D., deputy director of clinical research and special projects, NIAID, is available to comment. CONTACT: To schedule interviews, please contact Elizabeth Deatrick, (301) 402-1663, NIAIDNews@xxxxxxxxxxxxx. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.
News releases, fact sheets and other NIAID-related materials are available on the NIAID website. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <https://www.nih.gov>. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at: <https://www.nih.gov/news-events/news-releases/sars-cov-2-antigen-levels-linked-patient-outcomes> To subscribe (or unsubscribe) from NIH News Release mailings, go to <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |
